Data / Drug companies / Doxylamine succinate and pyridoxine hydrochloride
Doxylamine succinate and pyridoxine hydrochloride: 4 companies and 5 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Doxylamine succinate and pyridoxine hydrochloride is listed in the FDA National Drug Code Directory by 4 companies, with 5 products in commercial distribution. 2 of the products (40.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, delayed release; tablet, extended release, and the newest product started marketing on December 11, 2023.
The request: Get every company that lists doxylamine succinate and pyridoxine hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 4
- Products
- 5
- Generic (ANDA) products
- 2 (40.0%)
- Application numbers
- 4
- Routes
- Oral
- Brand names
- Bonjesta, Diclegis
- openFDA record search
- api.fda.gov
Companies that list doxylamine succinate and pyridoxine hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Duchesnay USA, Inc. | 2 | tablet, extended release; tablet, delayed release | New drug applications (NDA) | February 19, 2018 |
| Actavis Pharma, Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | June 21, 2019 |
| Analog Pharma | 1 | tablet, delayed release | Authorized generics (NDA) | November 15, 2018 |
| Bionpharma Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | December 11, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, delayed release | 4 | 80% |
| Tablet, extended release | 1 | 20% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 2 | 40% |
| New drug applications (NDA) | 2 | 40% |
| Authorized generics (NDA) | 1 | 20% |
Pharmacologic classes
| Class | Products |
|---|---|
| Antihistamine | 5 |
| Vitamin B6 Analog | 5 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.